MRNS stock forecast
Our latest prediction for Marinus Pharmaceuticals, Inc.'s stock price was made on the Dec. 19, 2017 when the stock price was at 7.60$.
In the short term (2weeks), MRNS's stock price should underperform the market by -2.67%. During that period the price should oscillate between -12.72% and +14.85%.
In the medium term (3months), MRNS's stock price should outperform the market by 0.61%. During that period the price should oscillate between -26.12% and +36.14%.Get email alerts
About Marinus Pharmaceuticals, Inc.
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -0.98$ per share.
The book value per share is 1.11$
Three months stock forecastDec. 19, 2017
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|